| 货号 | 13258-10g |
| 描述 | There are two homologous nuclear receptors for the hormone 17β-estradiol (estrogen), commonly called ERα and ERβ. Receptor activation leads to the formation of homo- and hetero-dimers, which in turn interact with accessory proteins to regulate gene transcription. Tamoxifen is a selective estrogen receptor modulator, evoking tissue-dependent effects. It is an antagonist of ER action in breast tissue and breast cancer cells and is reported to be effective in the treatment of early breast cancer to prevent tumor growth.1,2 Importantly, tamoxifen has been reported to act as an ER agonist in bone and blood vessels, helping to minimize osteoporosis and reduce the risk of cardiovascular disease in post-menopausal women.3 Also, tamoxifen is a partial ER agonist in uterine tissues and is reported to increase the risk of endometrial carcinoma.4 |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Horwitz, K.B., and McGuire, W.L. Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. The Journal of Biological Chemisty 253(22), 8185-8191 (1978). 2.Clarke, M.,Collins, R.,Davies, C., et al. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351, 1451-1467 (1998). 3.Tonetti, D.A., and Jordan, V.C. Targeted anti-estrogens to treat and prevent diseases in women. Mol. Med. Today 2(5), 218-223 (1996). 4.Jordan, V.C., and Assikis, V.J. Endometrial carcinoma and tamoxifen: Clearing up a controversy. Clinical Cancer Research 1(5), 467-472 (1995). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 371.5 |
| 分子式 | C26H29NO |
| CAS号 | 10540-29-1 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |